FOLFIRI+cetuximab

Phase 3Monoclonal antibody

NNational Cancer Institute, Naples

FOLFIRI+cetuximab is one of 54 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerRecruiting

Colorectal Cancer MetastaticNot yet recruiting

Colorectal CancerPhase 2

Recruiting

Colorectal Cancer MetastaticPhase 3

Not yet recruiting

Competition

Competitive Landscape

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 3

39 2

Adrucil

EElorac, Inc.

Phase 3

86 3

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

58 4

Acetylsalicylic Acid

Bayer

Phase 3

6 5

XL092

Roche

Phase 3

1 6

TAS 102

Taiho Oncology, Inc.

Phase 3

8 7

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2 8

Tucidinostat

CChipscreen Biosciences, Ltd.

Phase 3

1 9

FOLFIRI+cetuximab

NNational Cancer Institute, Naples

Phase 3

1 10

Intravenous Methylene Blue

CChinese University of Hong Kong

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Not yet recruiting

Colorectal Cancer Metastatic

NCT07004413

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

Recruiting·NNational Cancer Institute, Naples·Phase 2·NCT03874026·34 enrolled

Colorectal Cancer Metastatic1 trial

Randomized Study to Compare First-line Treatment With Either Continuous or Intermittent Cetuximab Plus FOLFIRI in Patients With RAS/BRAF-wild-type Metastatic Colorectal Cancer (mCRC): AIO-KRK-0524 / FIRE-11

Not yet recruiting·CCharite University, Berlin, Germany·Phase 3·NCT07004413·267 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FOLFIRI+cetuximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFIRI+cetuximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFIRI+cetuximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute, Naples company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute, Naples

FOLFIRI+cetuximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Colorectal Cancer1 trial

Colorectal Cancer Metastatic1 trial

References

Drug Info

Quick Facts

Related News